An Open-Label, Non-randomized, Prospective Biomarker Study to Assess Analytic Concordance Between Non-invasive Testing and Tissue Testing for EGFR T790M Mutation Detection in Patients With Non-small Cell Lung Cancer
Phase of Trial: Phase IV
Latest Information Update: 01 Aug 2018
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Diagnostic use
- Acronyms RADIANCE
- Sponsors AstraZeneca
- 11 Dec 2017 Planned End Date changed from 28 Sep 2020 to 31 May 2021.
- 11 Dec 2017 Planned primary completion date changed from 28 Sep 2020 to 31 May 2021.
- 11 Dec 2017 Status changed from not yet recruiting to recruiting.